synthetic peptide raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2025-09-24 and is reviewed periodically as new material appears.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Prohibited in sport | Listed by WADA under peptide hormones |
| WADA class | S2 | Peptide hormones, growth factors, related substances, and mimetics |
| Approved therapeutic use | Not established | Clinical research did not lead to broad marketing approval |
| Common detection method | LC-MS/MS | Liquid chromatography-tandem mass spectrometry |
| Sample preparation | Extraction and enrichment | Immunoaffinity or solid-phase extraction may be used |
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
Clown loaches are particularly susceptible to Ichthyophthirius (ich), or white spot disease. Due to the fact that clown loaches have small or no scales, they are often not treated with full doses of medications. Over-exploitation of C. macracanthus has motivated the development of conservation efforts, mostly new artificial propagation techniques. C. macracanthus is easier to breed when individuals are between two and four centimeters in size. In the wild, adults feed on worms, crustaceans and plant matter. Most clown loaches accept commercial flake food and sinking pellets as their dietary staple, but thrive with a variety of food: live (worms, brine shrimp, small snails), banana, other plant matter, freeze-dried (tubifex worms, especially if it is fortified) and frozen brine shrimp. Clown loaches (and their cousins) are also one of the few fishes that will eat bladder snails (Physella acuta), and are valued by aquarists for controlling this pest in planted aquaria.
== Motivation == Researcher Frederick Banting famously refused to put his name on the patent after discovering insulin in 1923. The original patent for insulin was later sold by his collaborators for just $1 to the University of Toronto in an effort to make it as available as possible. Despite this, for various reasons, there remains no generic version of insulin available in the US. Insulin remains controlled by a small number of large pharmaceutical companies and sold at prices unaffordable to many who rely on it to live, particularly those without insurance. This lack of availability has led to fatalities, such as Alec Smith, who died in 2017 due to lack of insulin. The Open Insulin Project is motivated by the urgent need to protect the health of those with diabetes regardless of their economic or employment status by developing low-cost methods for insulin production available for anyone to use.
== Trials == Howard Florey's team at Oxford showed that Penicillium extract killed many kinds of bacteria. Gardner and Orr-Ewing tested it against gonococcus (against which it was most effective), meningococcus, streptococcus, staphylococcus, Bacillus anthracis, actinomyces and tetanus bacterium (Clostridium tetani) and the bacteria that cause gangrene. They observed bacteria attempting to grow in the presence of penicillin, and noted that penicillin was neither an enzyme that broke the bacteria down, nor an antiseptic that killed them; rather, it was a chemical that interfered with the process of cell division. Jennings observed that it had no effect on white blood cells, and would therefore reinforce rather than hinder the body's natural defences against bacteria. She also found that unlike sulphonamides, the first and only effective broad-spectrum antibiotic available at the time, it was not destroyed by pus. Medawar found that it did not affect the growth of tissue cells.
Logan's Roadhouse serves American food. The chain's menu includes mesquite-grilled steaks, traditional American fare (sandwiches, soup, salads, and seafood), ice-cold longneck beer, homemade yeast rolls, and unlimited buckets of in-shell peanuts. Logan's serves appetizers, steak, and hamburgers, and offers side dishes such as salad, french fries, homestyle potato chips, rice pilaf and sweet or baked potatoes.
=== Investigations === Several sets of investigations, both congressional via the Senate Armed Services Committee, military via courts-martial, and criminal for non-military contractors, were launched in response to the scandal. Seymour Hersh, who exposed the Abu Ghraib scandal, and reports in Newsweek, has taken the case even further. In 2003, Donald Rumsfeld instituted a policy that "encouraged physical coercion and sexual humiliation of Iraqi prisoners in an effort to generate more intelligence about the growing insurgency in Iraq.". This policy stemmed from an earlier policy taken toward al-Qaeda prisoners. A memo to the Bush White House from counsel Alberto Gonzales claimed that the new sort of war renders the Geneva Conventions' limitations on interrogating enemy prisoners "obsolete". The program was approved by the CIA, NSA, and the National Security Council. President George W. Bush was informed of it. The Under Secretary of Defense for Intelligence Steven Cambone administered the operation. His deputy, William Boykin, instructed the head of operations at Camp X-ray Maj. Gen. Geoffrey Miller to do the same at Abu Ghraib. Miller told Brig. Gen. Janis Karpinski that the prison would now be dedicated to gathering intelligence. Douglas Feith and William Haynes were also involved in the operation. On May 18, 2004, a military intelligence analyst named Samuel Provance came out to the press, stating "There's definitely a cover-up".
Sources: en.wikipedia.org
==== Allosteric regulator ==== Acetyl-CoA serves as an allosteric regulator of pyruvate dehydrogenase kinase (PDK). It regulates through the ratio of acetyl-CoA versus CoA. Increased concentration of acetyl-CoA activates PDK. Acetyl-CoA is also an allosteric activator of pyruvate carboxylase.
Senate Majority Leader John Thune and U.S. Senate Republican Whip John Barrasso say that McConnell has spoken with them. July 8 2026 United States Senate elections: U.S. Senate Democratic Party nominee Graham Platner suspends his campaign in the upcoming U.S. Senate race in Maine amidst ongoing controversies surrounding his campaign, leaving the party to seek a replacement challenger to incumbent Republican Susan Collins. Iran war: The interim ceasefire between the United States and Iran breaks down after Iranian attacks on commercial vessels in the Strait of Hormuz. Trump declares the agreement "over", while saying that negotiations may continue. The U.S. Central Command says it struck around 90 Iranian military targets, including air defense, missile, drone and naval facilities. An additional U.S. strike hits a railway bridge in Golestan province on a trade route linking Iran with Russia and China. At the 2026 NATO summit in Ankara, Trump says that he has ordered Treasury Secretary Scott Bessent to halt all U.S. trade with Spain, calls Spain a "terrible partner" in NATO amid disputes over Spain's defense spending and the Iran War, and declares that the US will provide Ukraine a license to build Patriot missiles. July 9 Iran war: Trump says that Iran contacted him and they want to make an agreement. The U.S. Department of Justice announces that a federal grand jury has indicted eight men over an alleged plot to attack the UFC Freedom 250 event at the White House in Washington, D.C. last month.
The alpha-1B adrenergic receptor (α1B-adrenoreceptor), also known as ADRA1B, is an alpha-1 adrenergic receptor, and also denotes the human gene encoding it. The crystal structure of the α1B-adrenergic receptor has been determined in complex with the inverse agonist (+)-cyclazosin. There are 3 alpha-1 adrenergic receptor subtypes: alpha-1A, -1B and -1D, all of which signal through the Gq/11 family of G-proteins and different subtypes show different patterns of activation. They activate mitogenic responses and regulate growth and proliferation of many cells. This gene encodes alpha-1B-adrenergic receptor, which induces neoplastic transformation when transfected into NIH 3T3 fibroblasts and other cell lines. Thus, this normal cellular gene is identified as a protooncogene. This gene comprises 2 exons and a single large intron of at least 20 kb that interrupts the coding region. Antagonists L-765,314 Risperidone Brexpiprazole Tamsulosin Alpha-1B adrenergic receptor has been shown to interact with AP2M1. A role in regulation of dopaminergic neurotransmission has also been suggested.
mRNA display is a method to identify peptides which bind to a particular molecular target. The process utilizes two main components: an immobilized target and a peptide library in which each peptide is covalently linked to an mRNA:cDNA which encodes it. The immobilized target is mixed with the library in a binding step, then those peptide-mRNA:cDNA fusions which do not bind are washed away. The resulting mixture, which is enriched in peptide-mRNA:cDNA fusions that bind, is then amplified via a polymerase chain reaction (PCR). A new peptide library enriched in binding sequences is prepared from this cDNA, and the process is repeated for several rounds. The result is the isolation of nucleotides with sequences that encode peptides with high affinity for the target.
Sources: en.wikipedia.org
The increasing predominance of the divalent state well before the actinide series concludes is attributed to the relativistic stabilization of the 5f electrons, which increases with increasing atomic number: an effect of this is that nobelium is predominantly divalent instead of trivalent, unlike all the other lanthanides and actinides. In 1986, nobelium metal was estimated to have an enthalpy of sublimation between 126 kJ/mol, a value close to the values for einsteinium, fermium, and mendelevium and supporting the theory that nobelium would form a divalent metal. Like the other divalent late actinides (except the once again trivalent lawrencium), metallic nobelium should assume a face-centered cubic crystal structure. Divalent nobelium metal should have a metallic radius of around 197 pm. Nobelium's melting point has been predicted to be 800 °C, the same value as that estimated for the neighboring element mendelevium. Its density is predicted to be around 9.9 ± 0.4 g/cm3.
Drugs used in diabetes treat types of diabetes mellitus by decreasing glucose levels in the blood. Most GLP-1 receptor agonists (liraglutide, exenatide, tirzepatide, pramlintide and others) are administered by injection. Other anti-diabetes medications (including semaglutide as Rybelsus) are administered orally and are thus called oral hypoglycemic agents or oral antihyperglycemic agents. (Semaglutide is available both as a pill and as an injection.) There are different classes of hypoglycemic drugs, and selection of the appropriate agent depends on the nature of the diabetes (Type I vs Type II), the age and situation of the person, as well as other patient factors. Type 1 diabetes is an endocrine disorder characterized by hyperglycemia due to autoimmune destruction of insulin-secreting pancreatic beta cells. Insulin is a hormone needed by cells to take in glucose from the blood. Insufficient levels of insulin due to Type 1 diabetes can lead to chronic hyperglycemia and eventual multiorgan damage, resulting in renal, neurologic, cardiovascular, and other serious complications. The treatment for Type 1 diabetes involves regular insulin injections. Type 2 diabetes, the most common type of diabetes, occurs when cells exhibit insulin resistance and become unable to properly utilize insulin. Insulin resistance requires the pancreas to compensate by increasing insulin production. Once compensation fails, chronic hyperglycemia can manifest and type 2 diabetes develops.
Hashim Thaçi (born 24 April 1968) is a Kosovan politician who was the first prime minister of Kosovo (2008–2014) and the foreign minister and deputy prime minister (2014–2016) in the cabinet led by Isa Mustafa. He also served as president of Kosovo from 2016 until his resignation in 2020. Thaçi is from the region of Drenica in Kosovo, which is where the Kosovo Liberation Army (KLA) originated. He studied philosophy in Pristina before moving to Switzerland, where he joined the KLA in 1993. An Albanian nationalist, he rose through the ranks of the KLA to become leader of the most powerful faction by 1999, during the Rambouillet negotiations. He then joined the interim Kosovo administration after the war. Thaçi became leader of the Democratic Party of Kosovo (PDK), which won the largest share of the vote in the 2007 Kosovo elections. In 2008, Thaçi read the declaration of independence of Kosovo and became its first prime minister. In 2016 he was elected president of Kosovo. Thaçi pursued a pro-American policy while in office. In September 2026, Thaçi was convicted by the Kosovo Specialist Chambers' first instance Trial Panel of war crimes in the Kosovo War. Thaçi's defence lawyers stated that they would appeal the decision. In 2020, the Kosovo Specialist Chambers and Specialist Prosecutor's Office in The Hague filed a ten-count indictment against Thaçi and others, charging them with crimes against humanity and war crimes. To face these charges, Thaçi resigned from the presidency, stating that he did so to "protect the integrity of the presidency of Kosovo".
Sources: en.wikipedia.org
Yes, the World Anti-Doping Agency classifies AOD-9604 as a prohibited peptide hormone and related substance. Its use by athletes is banned under the relevant anti-doping code.
Confirmatory detection typically uses liquid chromatography with mass spectrometry. Immunoassays may be used for screening, but mass spectrometry provides structural confirmation.
No widely approved therapeutic indication exists for AOD-9604. It has been investigated in clinical studies, but regulatory approvals for general medical use are not established.
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.